# GDFATHER-NEO (NCT06059547)

> Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06059547
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: CatalYm GmbH
- Conditions: Bladder Cancer; Adult Solid Tumor
- Interventions: Nivolumab; Visugromab (CTL-002); Placebo
- Enrollment: 31
- Primary outcome: Pathological complete response rate
- Primary outcome: Radiological response rate according RECIST

## Indexed commentary on GDFATHER-NEO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 26
- YouTube: 3
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=gdfather-neo-nct06059547

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06059547", "email": "<work email>"}; the inbox owner confirms by the emailed link.